Snipr Biome CEO delighted over FDA fast-track status

CEO Christian Grøndahl now looks forward to more communication with the FDA, which could allow for Snipr Biome’s drug candidate to reach the market faster than before.
Christian Grøndahl, co-founder and CEO of Snipr Biome | Photo: EY / PR
Christian Grøndahl, co-founder and CEO of Snipr Biome | Photo: EY / PR
by CHRISTOPHER DUE KARLSSON, translated by daniel pedersen

Co-Founder and CEO at Snipr Biome Christian Grøndahl is very excited about the fact that the US Food and Drug Administration (FDA) recently awarded its special fast-track designation to the biotech company’s candidate, SNIPR001.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading